PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 10, 2013New England Journal of Medicine592 citationsOpen Access

Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

View Full Paper
KSKarl SwedbergJYJames B. YoungIAInder S. Anand

Key Points

  • To evaluate the efficacy and clinical impact of darbepoetin alfa in treating mild-to-moderate anemia among patients with systolic heart failure.
  • Interventional clinical trial (RED-HF, ClinicalTrials.gov NCT00358215) assessing darbepoetin alfa therapy in patients with systolic heart failure and concurrent mild-to-moderate anemia.
  • Treatment with darbepoetin alfa failed to improve clinical outcomes compared to standard management.
  • The findings do not support the clinical use of darbepoetin alfa for patients with systolic heart failure and mild-to-moderate anemia.

Abstract

Treatment with darbepoetin alfa did not improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia. Our findings do not support the use of darbepoetin alfa in these patients. (Funded by Amgen; RED-HF ClinicalTrials.gov number, NCT00358215.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Swedberg et al. (2013) studied this question.

synapsesocial.com/papers/69d752645f9a1dad5348fc49https://doi.org/10.1056/nejmoa1214865
Ask AI
Helpful
Bookmark
Share
View Full Paper